Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, efficacy and
safety of CAM2032 versus Eligard, in patients with prostate cancer. All patients will receive
leuprolide acetate administered subcutaneously once monthly during 3 months.